Table 5.
Factors affecting ORR achievement by logistic regression analysis
| Parameters | Univariate logistic regression | Multivariate logistic regression | ||||||
|---|---|---|---|---|---|---|---|---|
| P value | OR | 95% CI | P value | OR | 95% CI | |||
| Lower | Higher | Lower | Higher | |||||
| Age > =60 years | 0.328 | 0.630 | 0.250 | 1.590 | – | – | – | – |
| Gender (male) | 0.655 | 1.388 | 0.329 | 5.847 | – | – | – | – |
| HBV | 0.821 | 0.772 | 0.082 | 7.258 | – | – | – | – |
| HCV | 0.415 | 0.311 | 0.019 | 5.168 | – | – | – | – |
| Drink | 0.841 | 1.100 | 0.434 | 2.790 | – | – | – | – |
| Cirrhosis | 0.753 | 0.861 | 0.340 | 2.183 | – | – | – | – |
| Tumor distribution > = 20% | 0.765 | 0.993 | 0.384 | 2.566 | – | – | – | – |
| Number of nodules > 1 | 0.103 | 0.377 | 0.117 | 1.219 | – | – | – | – |
| Number of nodules > 3 | 0.058 | 0.400 | 0.155 | 1.031 | 0.381 | 0.618 | 0.211 | 1.813 |
| Largest nodule size > 3 cm | 0.270 | 1.692 | 0.664 | 4.313 | – | – | – | – |
| Largest nodule size > 5 cm | 0.785 | 0.879 | 0.349 | 2.216 | – | – | – | – |
| Portal vein invasion | 0.130 | 0.475 | 0.181 | 1.246 | – | – | – | – |
| Hepatic vein invasion | 0.526 | 0.686 | 0.213 | 2.204 | – | – | – | – |
| ECOG = 1 (vs. 0) | 0.596 | 1.327 | 0.466 | 3.778 | – | – | – | – |
| Child-pugh stage B (vs. stage A) | 0.432 | 2.368 | 0.276 | 20.285 | – | – | – | – |
| Higher BCLC stage | 0.073 | 0.560 | 0.297 | 1.056 | 0.178 | 0.600 | 0.285 | 1.262 |
| AFP abnormal | 0.432 | 0.745 | 0.290 | 1.918 | – | – | – | – |
| Previous cTACE | 0.093 | 0.449 | 0.177 | 1.142 | 0.095 | 0.433 | 0.162 | 1.158 |
| Previous surgery | 0.139 | 2.038 | 0.793 | 5.241 | – | – | – | – |
| Previous systematic chemotherapy | 0.821 | 1.296 | 0.138 | 12.186 | – | – | – | – |
| Previous radiofrequency ablation | 0.586 | 0.724 | 0.226 | 2.315 | – | – | – | – |
| Previous targeted therapy | – | – | – | – | – | – | – | – |
| Epirubicin (vs. Adriamycin) | – | – | – | – | – | – | – | – |
Data was presented as P value, OR (odds ratio) and 95% CI. Factors affecting ORR achievement were determined by univariate logistic regression analysis, while all factors with P value no less than 0.1 were further detected by multivariate logistic regression analysis. P Value < 0.05 was considered significant. Previous targeted therapy and Epirubicin (vs Adriamycin) were not able to be analyzed due to lack of effective events. BCLC score was defined as 0-Stage A, 1-Stage B, 2-Stage C to be analyzed in logistic model. HBV Hepatic b virus, HCV Hepatic c virus, ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP Alpha fetal protein, cTACE Conventional transarterial chemo-embolization